NASDAQ:PEPG PepGen Q3 2024 Earnings Report $3.11 -0.07 (-2.20%) As of 09/4/2026 04:00 PM Eastern ProfileEarnings HistoryForecast PepGen EPS ResultsActual EPS-$0.66Consensus EPS -$0.87Beat/MissBeat by +$0.21One Year Ago EPSN/APepGen Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APepGen Announcement DetailsQuarterQ3 2024Date11/7/2024TimeBefore Market OpensConference Call DateThursday, November 7, 2024Conference Call Time7:00AM ETUpcoming EarningsPepGen's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly Report(10-Q) PepGen Earnings HeadlinesDSMB approves dose escalation in PepGen’s FREEDOM2-DM1 studyAugust 7, 2026 | msn.comPepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB ReviewAugust 6, 2026 | businesswire.comHow to Think About a $500K Roth Conversion and the 35% BracketFor 2026, the 35 percent federal tax bracket starts at 512,450 dollars in taxable income for joint filers and 256,225 dollars for single filers. Converting a large IRA to a Roth in one year could push some income into that higher bracket. Some taxpayers spread conversions across multiple years to stay within a targeted bracket, factoring in Medicare surcharges and state taxes along the way. A fiduciary financial advisor can help evaluate conversion timing and tax impact for your specific situation. | SmartAsset (Ad)PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsAugust 6, 2026 | businesswire.comPepGen Inc. (PEPG) Stock Price, News, Quote & History - Yahoo FinanceJuly 14, 2026 | finance.yahoo.comPepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)July 8, 2026 | stockhouse.comSee More PepGen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PepGen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PepGen and other key companies, straight to your email. Email Address About PepGenPepGen (NASDAQ:PEPG) (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration. The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome). These in vivo gene editing candidates are engineered to restore enzyme activity in affected tissues, potentially reducing the burden of repeated interventions. Beyond lysosomal storage disorders, PepGen is advancing earlier-stage research in inherited cardiovascular and metabolic conditions leveraging the same platform. Founded in 2020 by a cohort of genome engineering scientists, PepGen has assembled an interdisciplinary team with expertise in translational research, clinical development and regulatory strategy. The company’s research operations are based in San Diego, where it maintains research laboratories and manufacturing collaborations. PepGen also partners with academic institutions and clinical centers across the United States to support preclinical studies and future clinical trial sites. Under the leadership of Chief Executive Officer David Becker, who previously held senior roles at multiple biotechnology firms, PepGen is preparing its pipeline for regulatory interactions and human trials. The company has initiated strategic alliances to extend its capabilities in vector production and to explore commercialization pathways in North America and Europe. View PepGen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/31 - 09/04Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key SignalLululemon’s Earnings Beat Hid a Bigger Problem for Its Turnaround StorySnowflake’s AI Momentum Is Forcing a Fresh Look at the StockAeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityGitLab’s AI Tools Are Starting to Turn Developer Demand Into Real RevenueMerchants Bancorp’s Rally Is Testing How Much Risk Investors Will Overlook Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
